Oxurion NV (0G99.L)
- GlobeNewswire
Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024
Oxurion Announces Results on the Annual Shareholders’ Meeting of 16 May 2024 Leuven, BELGIUM – 23 May, 2024 – 07.00 PM CET – Oxurion NV (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, held its annual shareholders’ meeting on May 16, 2024. The shareholders approved all items on the agenda of the annual shareholders’ meeting. All documents pertaining to the annual shareholders' meeting held on May 16, 2024, can be consulted on Oxurion’s website Oxurion/shareholders.
- GlobeNewswire
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas
Information on the Total Number of Voting Rights (Denominator) following Conversion Notice from Atlas Atlas Special Opportunities, LLC has converted 8 convertible bonds in Oxurion resulting in a EUR 200,000 capital increase. This is part of Atlas Special Opportunities, LLC’s EUR 20 million Capital Commitment1 that will allow Oxurion to focus on developing innovative therapeutics to preserve the vision of elderly people, targeting potential market opportunities of USD 3-6 billion. Leuven, BELGIUM
- GlobeNewswire
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC
Oxurion Receives Transparency Notification from Atlas Special Opportunities LLC Leuven, BELGIUM – May 16, 2024 – 07:00 PM CET (Euronext Brussels: OXUR), a biopharmaceutical company headquartered in Leuven, today announced that, pursuant to Belgian Transparency legislation1 it has received a transparency notification as follows: Oxurion received a transparency notification on May 16, 2024, from Atlas Special Opportunities, LLC indicating that as of May 13, 2024, it held 1,000,850,000 shares of th
